Milestones in Hematology and Oncology: From Fatal to Curable Disease

1. Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C et al. Trends and patterns of disparities in cancer mortality among US counties, 1980-2014. JAMA. 2017; 317(4):388–406.10.1001/jama.2016.20324 Search in Google Scholar

2. Diehl V, Thomas RK, Re D. Part II: Hodgkin’s lymphoma — Diagnosis and treatment. Lancet Oncol. 2004; 5(1):19-26.10.1016/S1470-2045(03)01320-2 Search in Google Scholar

3. Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012; 87(12):1096-1103.10.1002/ajh.2334823151980 Search in Google Scholar

4. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018; 93(5):704-715.10.1002/ajh.2507129634090 Search in Google Scholar

5. Ansell SM. Hodgkin Lymphoma: 2020 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020 May 8.10.1002/ajh.2585632384177 Search in Google Scholar

6. Cerci JJ, Linardi CC, Pracchia LF et al. 2-[18F]-fluoro-2-desoxy-D-glucose positron emission tomography initial staging impacts on survival in Hodgkin lymphoma. World J Radiol. 2013; 5(12):484-490.10.4329/wjr.v5.i12.484387450524379935 Search in Google Scholar

7. DeVita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970; 73(6):881–895.10.7326/0003-4819-73-6-8815525541 Search in Google Scholar

8. Longo DL, Young RC, Wesley M. et al. Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol. 1986; 4(9):1295-306.10.1200/JCO.1986.4.9.12953528400 Search in Google Scholar

9. Longo DL, Duffey PL, Young RC et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992; 10(2):210–218.10.1200/JCO.1992.10.2.2101732422 Search in Google Scholar

10. Kaldor JM, Day NE, Clarke EA et al. Leukemia following Hodgkin’s disease. N Engl J Med. 1990; 322(1):7–13.10.1056/NEJM1990010432201022403650 Search in Google Scholar

11. Karanfilski O. Diagnostic and clinical parameters and the treatment approach as prognostic factors in Hodgkin’s disease. PhD [dissertation]. Skopje, Republic of Macedonia, University Sts. Cyril and Methodius, Medical Faculty; 2000. Search in Google Scholar

12. Bonadonna G, Zucali R, Monfardini S et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975; 36(1):252-259.10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7 Search in Google Scholar

13. Amzai G. Evolution in the management, prognosis and quality of life in patients with Hodgkin’s lymphoma. PhD [dissertation]. Skopje, Republic of Macedonia, University Sts. Cyril and Methodius, Medical Faculty; 2018. Search in Google Scholar

14. Diehl V, Franklin J, Hasenclever D et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 1998; 16(12):3810-3821.10.1200/JCO.1998.16.12.3810 Search in Google Scholar

15. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemo-therapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003; 348(24):2386-2395.10.1056/NEJMoa022473 Search in Google Scholar

16. Federico M, Luminari S, Iannitto E et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s Lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009; 27(5):805–811.10.1200/JCO.2008.17.0910 Search in Google Scholar

17. Gianni AM, Rambaldi A, Zinzani PL et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the GITIL and IIL cooperative groups. Journal of Clinical Oncology. 2008; 26:abstract 8506.10.1200/jco.2008.26.15_suppl.8506 Search in Google Scholar

18. Viviani S, Zinzani PL, Rambaldi A et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011; 365(3):203–212.10.1056/NEJMoa1100340 Search in Google Scholar

19. Tam CS, Herschtal A, Seymour JF. ABVD versus BEACOPP for Hodgkin’s lymphoma. N Engl J Med. 2011; 365(16):1544–1545.10.1056/NEJMc1109618 Search in Google Scholar

20. Mounier N, Brice P, Bologna S et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014; 25(8):1622-1628.10.1093/annonc/mdu189 Search in Google Scholar

21. Collins GP, Parker AN, Pocock C et al. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol. 2014; 164(1):39-52.10.1111/bjh.12582 Search in Google Scholar

22. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011; 117(16):4208-4217.10.1182/blood-2010-09-288373 Search in Google Scholar

23. Nademanee A, O’Donnell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: results in 85 patients with analysis of prognostic factors. Blood. 1995; 85(5):1381–1390.10.1182/blood.V85.5.1381.bloodjournal8551381 Search in Google Scholar

24. Chopra R, McMillan AK, Linch DC et al. The place of high dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood. 1993; 81(5):1137–1145.10.1182/blood.V81.5.1137.1137 Search in Google Scholar

25. Sureda A, Arranz R, Iriondo A et al. Autologous stem cell transplantation for Hodgkin’s disease: Results and prognostic factors in 494 patients from the GEL/TAMO Spanish Cooperative Group. J Clin Oncol. 2001; 199(5):1395–1404.10.1200/JCO.2001.19.5.1395 Search in Google Scholar

26. Horning S, Fanale M, De Vos S et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. Ann Oncol. 2008; 19:abstract 118. Search in Google Scholar

27. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012; 30(18):2183–2189.10.1200/JCO.2011.38.0410 Search in Google Scholar

28. Chen R, Gopal AK, Smith SE et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016; 128(12):1562–1566.10.1182/blood-2016-02-699850 Search in Google Scholar

29. Younes A, Santoro A, Shipp M et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17(9):1283–1294.10.1016/S1470-2045(16)30167-X Search in Google Scholar

30. Chen R, Zinzani PL, Fanale MA et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017; 35(19):2125–2132.10.1200/JCO.2016.72.1316579184328441111 Search in Google Scholar

31. Moskowitz CH, Ribrag V, Michot J-M et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a phase 1b study (Keynote-013), Study. Keynote-013; ASH Meeting. 2014.10.1182/blood.V124.21.290.290 Search in Google Scholar

32. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015; 372(4):311–319.10.1056/NEJMoa1411087434800925482239 Search in Google Scholar

33. Armand P, Engert A, Younes A et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multi-cohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14):1428-1439.10.1200/JCO.2017.76.0793607585529584546 Search in Google Scholar

34. Armand P, Shipp MA, Ribrag V et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016; 34(31):3733-3739.10.1200/JCO.2016.67.3467579183827354476 Search in Google Scholar

35. Alvarez I, Sureda A, Caballero MD et al: Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006; 12(2):172-183.10.1016/j.bbmt.2005.09.00916443515 Search in Google Scholar

36. Sureda A, Canals C, Arranz R et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012; 97(2):310–317.10.3324/haematol.2011.045757326949421993674 Search in Google Scholar

37. Genadieva-Stavrik S, Boumendil A, Dreger P et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin’s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol 2016; 27(12):2251–2257.10.1093/annonc/mdw42128007754 Search in Google Scholar